-
Tebbutt, NC, Parry, MM, Zannino, D, Strickland, AH, Van Hazel, GA, Pavlakis, N, Ganju, V, Mellor, D, Dobrovic, A, Gebski, VJ, et al.
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.
British Journal of Cancer
108(4)
:
771 -774
2013
view publication
-
Price, TJ, Zannino, D, Wilson, K, Simes, RJ, Cassidy, J, Van Hazel, GA, Robinson, BA, Broad, A, Ganju, V, Ackland, SP, et al.
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Annals of Oncology
23(6)
:
1531 -1536
2012
view publication
-
Stockler, MR, Harvey, VJ, Francis, PA, Byrne, MJ, Ackland, SP, Fitzharris, B, Van Hazel, G, Wilcken, NRC, Grimison, PS, Nowak, AK, et al.
Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer.
Journal of Clinical Oncology
29(34)
:
4498 -4504
2011
view publication
-
Tebbutt, NC, Murphy, F, Zannino, D, Wilson, K, Cummins, MM, Abdi, E, Strickland, AH, Lowenthal, RM, Marx, G, Karapetis, C, et al.
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
Annals of Oncology
22(8)
:
1834 -1838
2011
view publication
-
Price, TJ, Zannino, D, Wilson, K, Simes, J, Van Hazel, GA, Robinson, BA, Broad, A, Ganju, V, Ackland, SP, Tebbutt, NC.
Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC)..
Journal of Clinical Oncology
29(15_suppl)
:
3621 -3621
2011
view publication